Special Editorial: When Prescribing Janus Kinase Inhibitors for Dermatologic Conditions, Be Mindful of the FDA’s 9/1/2021 Data Safety Communication

2021 ◽  
Author(s):  
Morgan Murphrey ◽  
Reid A. Waldman ◽  
Timothy Druso ◽  
Jane M. Grant-Kels
Keyword(s):  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Safety Communication ◽  
Janus Kinase Inhibitors ◽  
Data Safety

Hijaking the SARS-CoV-2 Cytokinopathy: Janus Kinase Inhibitors for Moderate to Severe COVID-19

2020 ◽  
Author(s):  
Christine Won ◽  
William Damsky ◽  
Inderjit Singh ◽  
Phillip Joseph ◽  
Astha Chichra ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

scholarly journals Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review

2021 ◽  
Author(s):  
Pedro Jesús Gómez-Arias ◽  
Francisco Gómez-García ◽  
Jorge Hernández-Parada ◽  
Ana María Montilla-López ◽  
Juan Ruano ◽  
...  
Keyword(s):  
Scoping Review ◽  
Kinase Inhibitors ◽  
Type I Interferon ◽  
Janus Kinase ◽  
Type I ◽  
Efficacy And Safety ◽  
Autoinflammatory Disorders ◽  
Janus Kinase Inhibitors

scholarly journals Clinical perspectives of Janus Kinase Inhibitors: A review

2021 ◽  
Vol 7 (2) ◽  
pp. 85-91
Author(s):  
Sadanand R. Mallurwar ◽  
Vinod K. Nakra ◽  
Mahesh R. Bhat
Keyword(s):  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

scholarly journals Epidemiological profile of patients using janus kinase inhibitors in a tertiary center.

2021 ◽  
Author(s):  
Stan Richard Medeiros de Souza ◽  
Marina de Azevedo Martins ◽  
Lucas Guimarães Nolasco Farias ◽  
José Victor Martinez ◽  
Renata Maria Monteiro Pinto ◽  
...  
Keyword(s):  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors ◽  
Tertiary Center ◽  
Epidemiological Profile

, , , , , , , , , ,

Sign in / Sign up

Export Citation Format

Share Document